nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—hematologic cancer—muscle cancer	0.674	1	CtDrD
Bortezomib—CYP1A1—Dacarbazine—muscle cancer	0.0387	0.348	CbGbCtD
Bortezomib—PTGS1—Etoposide—muscle cancer	0.019	0.17	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—muscle cancer	0.0173	0.155	CbGbCtD
Bortezomib—CYP2C8—Etoposide—muscle cancer	0.0109	0.0981	CbGbCtD
Bortezomib—CYP1A2—Etoposide—muscle cancer	0.00847	0.076	CbGbCtD
Bortezomib—CYP3A4—Vincristine—muscle cancer	0.00484	0.0434	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—muscle cancer	0.00476	0.0427	CbGbCtD
Bortezomib—CYP3A4—Etoposide—muscle cancer	0.00444	0.0398	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—muscle cancer	0.00303	0.0271	CbGbCtD
Bortezomib—PSMA1—embryo—muscle cancer	0.00191	0.0352	CbGeAlD
Bortezomib—PSMA1—renal system—muscle cancer	0.00144	0.0267	CbGeAlD
Bortezomib—PSMD2—embryo—muscle cancer	0.00142	0.0262	CbGeAlD
Bortezomib—CTSG—cardiac atrium—muscle cancer	0.00135	0.0249	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—muscle cancer	0.00126	0.0232	CbGeAlD
Bortezomib—CTSG—tendon—muscle cancer	0.00117	0.0217	CbGeAlD
Bortezomib—CTSG—bone marrow—muscle cancer	0.00114	0.021	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—muscle cancer	0.00111	0.0206	CbGeAlD
Bortezomib—PSMA1—bone marrow—muscle cancer	0.00109	0.0202	CbGeAlD
Bortezomib—CTSG—vagina—muscle cancer	0.00109	0.0201	CbGeAlD
Bortezomib—PSMB1—embryo—muscle cancer	0.00109	0.0201	CbGeAlD
Bortezomib—PSMD1—cardiac atrium—muscle cancer	0.00108	0.02	CbGeAlD
Bortezomib—PSMD2—renal system—muscle cancer	0.00107	0.0198	CbGeAlD
Bortezomib—PSMB2—embryo—muscle cancer	0.00106	0.0196	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vincristine—muscle cancer	0.00102	0.5	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—muscle cancer	0.00102	0.5	CbGdCrCtD
Bortezomib—PSMB5—smooth muscle tissue—muscle cancer	0.000978	0.0181	CbGeAlD
Bortezomib—CTSG—testis—muscle cancer	0.000971	0.0179	CbGeAlD
Bortezomib—PSMA1—head—muscle cancer	0.000965	0.0178	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—muscle cancer	0.00096	0.0178	CbGeAlD
Bortezomib—PSMD1—tendon—muscle cancer	0.000945	0.0175	CbGeAlD
Bortezomib—PSMA1—testis—muscle cancer	0.000932	0.0172	CbGeAlD
Bortezomib—PSMD1—bone marrow—muscle cancer	0.000915	0.0169	CbGeAlD
Bortezomib—PSMD1—vagina—muscle cancer	0.000877	0.0162	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—muscle cancer	0.000855	0.0158	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—muscle cancer	0.000843	0.0156	CbGeAlD
Bortezomib—PSMD2—tendon—muscle cancer	0.000837	0.0155	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—muscle cancer	0.000834	0.0154	CbGeAlD
Bortezomib—PSMB8—tendon—muscle cancer	0.000832	0.0154	CbGeAlD
Bortezomib—PSMB1—renal system—muscle cancer	0.000823	0.0152	CbGeAlD
Bortezomib—PSMD2—bone marrow—muscle cancer	0.000811	0.015	CbGeAlD
Bortezomib—PSMB8—bone marrow—muscle cancer	0.000806	0.0149	CbGeAlD
Bortezomib—PSMB2—renal system—muscle cancer	0.000803	0.0148	CbGeAlD
Bortezomib—PSMD1—testis—muscle cancer	0.000782	0.0145	CbGeAlD
Bortezomib—PSMD2—vagina—muscle cancer	0.000777	0.0144	CbGeAlD
Bortezomib—PSMB8—vagina—muscle cancer	0.000772	0.0143	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—muscle cancer	0.000737	0.0136	CbGeAlD
Bortezomib—PSMB5—tendon—muscle cancer	0.000735	0.0136	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—muscle cancer	0.000719	0.0133	CbGeAlD
Bortezomib—PSMD2—head—muscle cancer	0.000717	0.0133	CbGeAlD
Bortezomib—PSMB5—bone marrow—muscle cancer	0.000712	0.0132	CbGeAlD
Bortezomib—SLC31A1—renal system—muscle cancer	0.000695	0.0129	CbGeAlD
Bortezomib—PSMD2—testis—muscle cancer	0.000693	0.0128	CbGeAlD
Bortezomib—PSMB8—testis—muscle cancer	0.000689	0.0127	CbGeAlD
Bortezomib—PSMB5—vagina—muscle cancer	0.000682	0.0126	CbGeAlD
Bortezomib—PSMB1—tendon—muscle cancer	0.000642	0.0119	CbGeAlD
Bortezomib—PSMB2—tendon—muscle cancer	0.000627	0.0116	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—muscle cancer	0.000623	0.0115	CbGeAlD
Bortezomib—PSMB1—bone marrow—muscle cancer	0.000622	0.0115	CbGeAlD
Bortezomib—PSMB5—testis—muscle cancer	0.000609	0.0112	CbGeAlD
Bortezomib—PSMB2—bone marrow—muscle cancer	0.000607	0.0112	CbGeAlD
Bortezomib—PSMB1—vagina—muscle cancer	0.000596	0.011	CbGeAlD
Bortezomib—PSMB2—vagina—muscle cancer	0.000582	0.0108	CbGeAlD
Bortezomib—PSMB1—head—muscle cancer	0.000551	0.0102	CbGeAlD
Bortezomib—SLC31A1—tendon—muscle cancer	0.000543	0.01	CbGeAlD
Bortezomib—PSMB2—head—muscle cancer	0.000537	0.00993	CbGeAlD
Bortezomib—PSMB1—testis—muscle cancer	0.000532	0.00983	CbGeAlD
Bortezomib—SLC31A1—bone marrow—muscle cancer	0.000526	0.00972	CbGeAlD
Bortezomib—PSMB2—testis—muscle cancer	0.000519	0.00959	CbGeAlD
Bortezomib—SLC31A1—vagina—muscle cancer	0.000504	0.00931	CbGeAlD
Bortezomib—SLC31A1—head—muscle cancer	0.000465	0.0086	CbGeAlD
Bortezomib—SLC31A1—testis—muscle cancer	0.000449	0.00831	CbGeAlD
Bortezomib—CYP2C8—renal system—muscle cancer	0.000256	0.00473	CbGeAlD
Bortezomib—CYP1A2—renal system—muscle cancer	0.000239	0.00443	CbGeAlD
Bortezomib—CYP1A1—renal system—muscle cancer	0.000236	0.00437	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—muscle cancer	0.000216	0.00398	CbGeAlD
Bortezomib—CYP2C19—vagina—muscle cancer	0.000212	0.00392	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—muscle cancer	0.000211	0.00391	CbGeAlD
Bortezomib—PTGS1—renal system—muscle cancer	0.000207	0.00384	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—muscle cancer	0.000186	0.00343	CbGeAlD
Bortezomib—CYP2C8—vagina—muscle cancer	0.000185	0.00343	CbGeAlD
Bortezomib—CYP3A4—renal system—muscle cancer	0.000173	0.0032	CbGeAlD
Bortezomib—CYP1A1—vagina—muscle cancer	0.000171	0.00316	CbGeAlD
Bortezomib—CYP2D6—renal system—muscle cancer	0.000171	0.00315	CbGeAlD
Bortezomib—CYP2C8—testis—muscle cancer	0.000165	0.00306	CbGeAlD
Bortezomib—PTGS1—tendon—muscle cancer	0.000162	0.00299	CbGeAlD
Bortezomib—CYP1A1—head—muscle cancer	0.000158	0.00292	CbGeAlD
Bortezomib—PTGS1—vagina—muscle cancer	0.00015	0.00278	CbGeAlD
Bortezomib—PTGS1—head—muscle cancer	0.000139	0.00257	CbGeAlD
Bortezomib—PTGS1—testis—muscle cancer	0.000134	0.00248	CbGeAlD
Bortezomib—CYP2D6—head—muscle cancer	0.000114	0.00211	CbGeAlD
Bortezomib—CYP2D6—testis—muscle cancer	0.00011	0.00204	CbGeAlD
Bortezomib—Gastrointestinal pain—Vincristine—muscle cancer	6.12e-05	0.0006	CcSEcCtD
Bortezomib—Confusional state—Etoposide—muscle cancer	6.11e-05	0.000599	CcSEcCtD
Bortezomib—Cardiac arrest—Doxorubicin—muscle cancer	6.08e-05	0.000596	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—muscle cancer	6.06e-05	0.000594	CcSEcCtD
Bortezomib—Anaphylactic shock—Etoposide—muscle cancer	6.06e-05	0.000594	CcSEcCtD
Bortezomib—Infection—Etoposide—muscle cancer	6.02e-05	0.00059	CcSEcCtD
Bortezomib—Ataxia—Doxorubicin—muscle cancer	6.01e-05	0.00059	CcSEcCtD
Bortezomib—Asthenia—Dactinomycin—muscle cancer	6.01e-05	0.000589	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—muscle cancer	5.97e-05	0.000585	CcSEcCtD
Bortezomib—Dehydration—Doxorubicin—muscle cancer	5.95e-05	0.000583	CcSEcCtD
Bortezomib—Thrombocytopenia—Etoposide—muscle cancer	5.93e-05	0.000582	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Methotrexate—muscle cancer	5.93e-05	0.000582	CcSEcCtD
Bortezomib—Tachycardia—Etoposide—muscle cancer	5.91e-05	0.00058	CcSEcCtD
Bortezomib—Body temperature increased—Vincristine—muscle cancer	5.91e-05	0.00058	CcSEcCtD
Bortezomib—Abdominal pain—Vincristine—muscle cancer	5.91e-05	0.00058	CcSEcCtD
Bortezomib—Skin disorder—Etoposide—muscle cancer	5.88e-05	0.000577	CcSEcCtD
Bortezomib—Erectile dysfunction—Methotrexate—muscle cancer	5.88e-05	0.000576	CcSEcCtD
Bortezomib—Dry skin—Doxorubicin—muscle cancer	5.86e-05	0.000575	CcSEcCtD
Bortezomib—Hyperhidrosis—Etoposide—muscle cancer	5.86e-05	0.000574	CcSEcCtD
Bortezomib—Abdominal pain upper—Doxorubicin—muscle cancer	5.84e-05	0.000573	CcSEcCtD
Bortezomib—Orthostatic hypotension—Doxorubicin—muscle cancer	5.84e-05	0.000573	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—muscle cancer	5.82e-05	0.000571	CcSEcCtD
Bortezomib—Hypokalaemia—Doxorubicin—muscle cancer	5.82e-05	0.000571	CcSEcCtD
Bortezomib—Breast disorder—Doxorubicin—muscle cancer	5.78e-05	0.000567	CcSEcCtD
Bortezomib—Anorexia—Etoposide—muscle cancer	5.77e-05	0.000566	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	5.76e-05	0.000565	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—muscle cancer	5.73e-05	0.000562	CcSEcCtD
Bortezomib—Pneumonia—Methotrexate—muscle cancer	5.72e-05	0.000561	CcSEcCtD
Bortezomib—Nasopharyngitis—Doxorubicin—muscle cancer	5.72e-05	0.000561	CcSEcCtD
Bortezomib—Infestation NOS—Methotrexate—muscle cancer	5.69e-05	0.000558	CcSEcCtD
Bortezomib—Infestation—Methotrexate—muscle cancer	5.69e-05	0.000558	CcSEcCtD
Bortezomib—Hypotension—Etoposide—muscle cancer	5.66e-05	0.000555	CcSEcCtD
Bortezomib—Gastritis—Doxorubicin—muscle cancer	5.66e-05	0.000555	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	5.64e-05	0.000553	CcSEcCtD
Bortezomib—Muscular weakness—Doxorubicin—muscle cancer	5.64e-05	0.000553	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—muscle cancer	5.59e-05	0.000549	CcSEcCtD
Bortezomib—Abdominal distension—Doxorubicin—muscle cancer	5.56e-05	0.000546	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—muscle cancer	5.55e-05	0.000544	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—muscle cancer	5.53e-05	0.000542	CcSEcCtD
Bortezomib—Influenza—Doxorubicin—muscle cancer	5.53e-05	0.000542	CcSEcCtD
Bortezomib—Dysphagia—Doxorubicin—muscle cancer	5.53e-05	0.000542	CcSEcCtD
Bortezomib—Hypersensitivity—Vincristine—muscle cancer	5.51e-05	0.00054	CcSEcCtD
Bortezomib—Paraesthesia—Etoposide—muscle cancer	5.44e-05	0.000534	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—muscle cancer	5.43e-05	0.000532	CcSEcCtD
Bortezomib—Pancreatitis—Doxorubicin—muscle cancer	5.42e-05	0.000531	CcSEcCtD
Bortezomib—Dyspnoea—Etoposide—muscle cancer	5.4e-05	0.00053	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—muscle cancer	5.38e-05	0.000528	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—muscle cancer	5.38e-05	0.000528	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—muscle cancer	5.37e-05	0.000526	CcSEcCtD
Bortezomib—Asthenia—Vincristine—muscle cancer	5.37e-05	0.000526	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—muscle cancer	5.32e-05	0.000522	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—muscle cancer	5.31e-05	0.000521	CcSEcCtD
Bortezomib—Rash—Dactinomycin—muscle cancer	5.28e-05	0.000518	CcSEcCtD
Bortezomib—Decreased appetite—Etoposide—muscle cancer	5.27e-05	0.000517	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—muscle cancer	5.25e-05	0.000515	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Etoposide—muscle cancer	5.23e-05	0.000513	CcSEcCtD
Bortezomib—Fatigue—Etoposide—muscle cancer	5.22e-05	0.000512	CcSEcCtD
Bortezomib—Pain—Etoposide—muscle cancer	5.18e-05	0.000508	CcSEcCtD
Bortezomib—Constipation—Etoposide—muscle cancer	5.18e-05	0.000508	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—muscle cancer	5.17e-05	0.000507	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.14e-05	0.000504	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—muscle cancer	5.13e-05	0.000503	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—muscle cancer	5.12e-05	0.000502	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—muscle cancer	5.11e-05	0.000501	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—muscle cancer	5.11e-05	0.000501	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—muscle cancer	5.1e-05	0.000501	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—muscle cancer	5.04e-05	0.000495	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—muscle cancer	5.04e-05	0.000495	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—muscle cancer	5.03e-05	0.000493	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—muscle cancer	5.01e-05	0.000491	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—muscle cancer	5e-05	0.00049	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—muscle cancer	4.99e-05	0.00049	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—muscle cancer	4.98e-05	0.000489	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—muscle cancer	4.97e-05	0.000488	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—muscle cancer	4.96e-05	0.000486	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—muscle cancer	4.95e-05	0.000486	CcSEcCtD
Bortezomib—Dizziness—Vincristine—muscle cancer	4.95e-05	0.000485	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—muscle cancer	4.93e-05	0.000483	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—muscle cancer	4.93e-05	0.000483	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—muscle cancer	4.92e-05	0.000483	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	4.88e-05	0.000479	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—muscle cancer	4.84e-05	0.000475	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—muscle cancer	4.83e-05	0.000474	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—muscle cancer	4.83e-05	0.000474	CcSEcCtD
Bortezomib—Urticaria—Etoposide—muscle cancer	4.81e-05	0.000472	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—muscle cancer	4.8e-05	0.000471	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—muscle cancer	4.79e-05	0.00047	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—muscle cancer	4.79e-05	0.00047	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—muscle cancer	4.79e-05	0.00047	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—muscle cancer	4.79e-05	0.00047	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—muscle cancer	4.77e-05	0.000468	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—muscle cancer	4.76e-05	0.000467	CcSEcCtD
Bortezomib—Vomiting—Vincristine—muscle cancer	4.76e-05	0.000466	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—muscle cancer	4.74e-05	0.000465	CcSEcCtD
Bortezomib—Rash—Vincristine—muscle cancer	4.72e-05	0.000462	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—muscle cancer	4.71e-05	0.000462	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—muscle cancer	4.7e-05	0.000461	CcSEcCtD
Bortezomib—Headache—Vincristine—muscle cancer	4.69e-05	0.000459	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—muscle cancer	4.66e-05	0.000457	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—muscle cancer	4.65e-05	0.000456	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—muscle cancer	4.63e-05	0.000454	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—muscle cancer	4.62e-05	0.000453	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—muscle cancer	4.61e-05	0.000452	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—muscle cancer	4.6e-05	0.000451	CcSEcCtD
Bortezomib—Chills—Methotrexate—muscle cancer	4.58e-05	0.000449	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—muscle cancer	4.5e-05	0.000442	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—muscle cancer	4.47e-05	0.000439	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—muscle cancer	4.46e-05	0.000438	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—muscle cancer	4.45e-05	0.000436	CcSEcCtD
Bortezomib—Erythema—Methotrexate—muscle cancer	4.45e-05	0.000436	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—muscle cancer	4.45e-05	0.000436	CcSEcCtD
Bortezomib—Nausea—Vincristine—muscle cancer	4.44e-05	0.000436	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—muscle cancer	4.42e-05	0.000434	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—muscle cancer	4.42e-05	0.000434	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—muscle cancer	4.4e-05	0.000432	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—muscle cancer	4.37e-05	0.000428	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—muscle cancer	4.36e-05	0.000427	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—muscle cancer	4.35e-05	0.000427	CcSEcCtD
Bortezomib—Asthenia—Etoposide—muscle cancer	4.35e-05	0.000426	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—muscle cancer	4.35e-05	0.000426	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—muscle cancer	4.34e-05	0.000425	CcSEcCtD
Bortezomib—Back pain—Methotrexate—muscle cancer	4.3e-05	0.000422	CcSEcCtD
Bortezomib—Pruritus—Etoposide—muscle cancer	4.29e-05	0.00042	CcSEcCtD
Bortezomib—PSMB8—Gene Expression—MED12—muscle cancer	4.28e-05	0.000753	CbGpPWpGaD
Bortezomib—Visual impairment—Doxorubicin—muscle cancer	4.26e-05	0.000418	CcSEcCtD
Bortezomib—PSMD1—Immune System—FOXO4—muscle cancer	4.26e-05	0.00075	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—FOXO4—muscle cancer	4.24e-05	0.000746	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.23e-05	0.000744	CbGpPWpGaD
Bortezomib—Vision blurred—Methotrexate—muscle cancer	4.19e-05	0.000411	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—muscle cancer	4.18e-05	0.00041	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—muscle cancer	4.15e-05	0.000407	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—muscle cancer	4.13e-05	0.000405	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—muscle cancer	4.13e-05	0.000405	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—muscle cancer	4.12e-05	0.000404	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—muscle cancer	4.11e-05	0.000403	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—muscle cancer	4.1e-05	0.000403	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—muscle cancer	4.1e-05	0.000403	CcSEcCtD
Bortezomib—PSMA1—Metabolism—ENO2—muscle cancer	4.06e-05	0.000714	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TP53—muscle cancer	4.06e-05	0.000713	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TP53—muscle cancer	4.06e-05	0.000713	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TP53—muscle cancer	4.06e-05	0.000713	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ENO2—muscle cancer	4.04e-05	0.000711	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ENO2—muscle cancer	4.02e-05	0.000708	CbGpPWpGaD
Bortezomib—Angiopathy—Doxorubicin—muscle cancer	4.01e-05	0.000394	CcSEcCtD
Bortezomib—Malaise—Methotrexate—muscle cancer	4.01e-05	0.000393	CcSEcCtD
Bortezomib—Dizziness—Etoposide—muscle cancer	4.01e-05	0.000393	CcSEcCtD
Bortezomib—PSMB8—Apoptosis—TP53—muscle cancer	4e-05	0.000703	CbGpPWpGaD
Bortezomib—Immune system disorder—Doxorubicin—muscle cancer	3.99e-05	0.000392	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—muscle cancer	3.99e-05	0.000392	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—muscle cancer	3.99e-05	0.000391	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—muscle cancer	3.98e-05	0.00039	CcSEcCtD
Bortezomib—PSMA1—Adaptive Immune System—KIT—muscle cancer	3.97e-05	0.000699	CbGpPWpGaD
Bortezomib—Chills—Doxorubicin—muscle cancer	3.97e-05	0.000389	CcSEcCtD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.96e-05	0.000697	CbGpPWpGaD
Bortezomib—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	3.96e-05	0.000696	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KIT—muscle cancer	3.95e-05	0.000695	CbGpPWpGaD
Bortezomib—PSMA1—Disease—FOXO4—muscle cancer	3.95e-05	0.000695	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—FOXO1—muscle cancer	3.95e-05	0.000695	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—FOXO1—muscle cancer	3.95e-05	0.000695	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—FOXO1—muscle cancer	3.95e-05	0.000695	CbGpPWpGaD
Bortezomib—Arrhythmia—Doxorubicin—muscle cancer	3.95e-05	0.000387	CcSEcCtD
Bortezomib—PSMA1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.94e-05	0.000693	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KIT—muscle cancer	3.94e-05	0.000692	CbGpPWpGaD
Bortezomib—PSMD1—Disease—FOXO4—muscle cancer	3.94e-05	0.000692	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.92e-05	0.000689	CbGpPWpGaD
Bortezomib—PSMD2—Disease—FOXO4—muscle cancer	3.92e-05	0.000689	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.9e-05	0.000686	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—FOXO1—muscle cancer	3.9e-05	0.000685	CbGpPWpGaD
Bortezomib—Cough—Methotrexate—muscle cancer	3.88e-05	0.000381	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—muscle cancer	3.87e-05	0.00038	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—muscle cancer	3.85e-05	0.000378	CcSEcCtD
Bortezomib—Vomiting—Etoposide—muscle cancer	3.85e-05	0.000378	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—muscle cancer	3.85e-05	0.000378	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—muscle cancer	3.85e-05	0.000378	CcSEcCtD
Bortezomib—Rash—Etoposide—muscle cancer	3.82e-05	0.000375	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—muscle cancer	3.82e-05	0.000374	CcSEcCtD
Bortezomib—Headache—Etoposide—muscle cancer	3.8e-05	0.000372	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—muscle cancer	3.79e-05	0.000372	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—muscle cancer	3.79e-05	0.000371	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—muscle cancer	3.79e-05	0.000371	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—muscle cancer	3.79e-05	0.000371	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—muscle cancer	3.77e-05	0.00037	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.76e-05	0.000369	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—muscle cancer	3.74e-05	0.000367	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—muscle cancer	3.72e-05	0.000365	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—muscle cancer	3.7e-05	0.000363	CcSEcCtD
Bortezomib—PSMB2—Disease—ENO2—muscle cancer	3.68e-05	0.000646	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ENO2—muscle cancer	3.68e-05	0.000646	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ENO2—muscle cancer	3.68e-05	0.000646	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—muscle cancer	3.66e-05	0.000359	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—muscle cancer	3.63e-05	0.000356	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—muscle cancer	3.63e-05	0.000356	CcSEcCtD
Bortezomib—PSMB8—Disease—ENO2—muscle cancer	3.62e-05	0.000637	CbGpPWpGaD
Bortezomib—Infection—Methotrexate—muscle cancer	3.61e-05	0.000354	CcSEcCtD
Bortezomib—Nausea—Etoposide—muscle cancer	3.6e-05	0.000353	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—muscle cancer	3.57e-05	0.00035	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—muscle cancer	3.56e-05	0.000349	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—muscle cancer	3.56e-05	0.000349	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—muscle cancer	3.55e-05	0.000348	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—muscle cancer	3.54e-05	0.000347	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—muscle cancer	3.52e-05	0.000346	CcSEcCtD
Bortezomib—PSMA1—Cell Cycle—CDKN2A—muscle cancer	3.52e-05	0.000619	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Methotrexate—muscle cancer	3.51e-05	0.000344	CcSEcCtD
Bortezomib—PSMD1—Cell Cycle—CDKN2A—muscle cancer	3.51e-05	0.000616	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—CDKN2A—muscle cancer	3.49e-05	0.000613	CbGpPWpGaD
Bortezomib—Malaise—Doxorubicin—muscle cancer	3.47e-05	0.000341	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—muscle cancer	3.46e-05	0.000339	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—muscle cancer	3.46e-05	0.000339	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—muscle cancer	3.45e-05	0.000339	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—muscle cancer	3.45e-05	0.000338	CcSEcCtD
Bortezomib—PSMA1—Cell Cycle—MDM2—muscle cancer	3.42e-05	0.000601	CbGpPWpGaD
Bortezomib—Palpitations—Doxorubicin—muscle cancer	3.4e-05	0.000334	CcSEcCtD
Bortezomib—PSMD1—Cell Cycle—MDM2—muscle cancer	3.4e-05	0.000598	CbGpPWpGaD
Bortezomib—Hypotension—Methotrexate—muscle cancer	3.39e-05	0.000333	CcSEcCtD
Bortezomib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	3.39e-05	0.000595	CbGpPWpGaD
Bortezomib—Loss of consciousness—Doxorubicin—muscle cancer	3.38e-05	0.000332	CcSEcCtD
Bortezomib—PSMD2—Cell Cycle—MDM2—muscle cancer	3.38e-05	0.000595	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—MED12—muscle cancer	3.38e-05	0.000594	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—MED12—muscle cancer	3.38e-05	0.000594	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—MED12—muscle cancer	3.38e-05	0.000594	CbGpPWpGaD
Bortezomib—Cough—Doxorubicin—muscle cancer	3.36e-05	0.000329	CcSEcCtD
Bortezomib—PSMB1—Disease—HMGA1—muscle cancer	3.34e-05	0.000588	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HMGA1—muscle cancer	3.34e-05	0.000588	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HMGA1—muscle cancer	3.34e-05	0.000588	CbGpPWpGaD
Bortezomib—Convulsion—Doxorubicin—muscle cancer	3.34e-05	0.000327	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.33e-05	0.000586	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—MED12—muscle cancer	3.33e-05	0.000585	CbGpPWpGaD
Bortezomib—Hypertension—Doxorubicin—muscle cancer	3.32e-05	0.000326	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.31e-05	0.000324	CcSEcCtD
Bortezomib—PSMB8—Disease—HMGA1—muscle cancer	3.29e-05	0.000579	CbGpPWpGaD
Bortezomib—Insomnia—Methotrexate—muscle cancer	3.28e-05	0.000322	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—muscle cancer	3.28e-05	0.000321	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—muscle cancer	3.28e-05	0.000321	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—muscle cancer	3.28e-05	0.000321	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—muscle cancer	3.27e-05	0.00032	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—muscle cancer	3.26e-05	0.00032	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.26e-05	0.000319	CcSEcCtD
Bortezomib—PSMB1—Immune System—FOXO4—muscle cancer	3.25e-05	0.000571	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—FOXO4—muscle cancer	3.25e-05	0.000571	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—FOXO4—muscle cancer	3.25e-05	0.000571	CbGpPWpGaD
Bortezomib—Discomfort—Doxorubicin—muscle cancer	3.24e-05	0.000318	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—muscle cancer	3.24e-05	0.000317	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—PTCH1—muscle cancer	3.22e-05	0.000566	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PTCH1—muscle cancer	3.2e-05	0.000564	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—FOXO4—muscle cancer	3.2e-05	0.000563	CbGpPWpGaD
Bortezomib—Dyspepsia—Methotrexate—muscle cancer	3.19e-05	0.000313	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—PTCH1—muscle cancer	3.19e-05	0.000561	CbGpPWpGaD
Bortezomib—Confusional state—Doxorubicin—muscle cancer	3.17e-05	0.000311	CcSEcCtD
Bortezomib—PSMA1—Immune System—FOXO1—muscle cancer	3.16e-05	0.000556	CbGpPWpGaD
Bortezomib—Decreased appetite—Methotrexate—muscle cancer	3.15e-05	0.000309	CcSEcCtD
Bortezomib—PSMD1—Immune System—FOXO1—muscle cancer	3.15e-05	0.000554	CbGpPWpGaD
Bortezomib—Anaphylactic shock—Doxorubicin—muscle cancer	3.14e-05	0.000308	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—muscle cancer	3.14e-05	0.000308	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.13e-05	0.000307	CcSEcCtD
Bortezomib—PSMD2—Immune System—FOXO1—muscle cancer	3.13e-05	0.000551	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—MDM2—muscle cancer	3.13e-05	0.00055	CbGpPWpGaD
Bortezomib—Fatigue—Methotrexate—muscle cancer	3.13e-05	0.000307	CcSEcCtD
Bortezomib—PTGS1—Metabolism—FH—muscle cancer	3.12e-05	0.000549	CbGpPWpGaD
Bortezomib—Infection—Doxorubicin—muscle cancer	3.12e-05	0.000306	CcSEcCtD
Bortezomib—PSMD1—Adaptive Immune System—MDM2—muscle cancer	3.11e-05	0.000548	CbGpPWpGaD
Bortezomib—Pain—Methotrexate—muscle cancer	3.1e-05	0.000304	CcSEcCtD
Bortezomib—PSMD2—Adaptive Immune System—MDM2—muscle cancer	3.1e-05	0.000545	CbGpPWpGaD
Bortezomib—Shock—Doxorubicin—muscle cancer	3.09e-05	0.000303	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—muscle cancer	3.08e-05	0.000302	CcSEcCtD
Bortezomib—PSMB5—Metabolism—ENO2—muscle cancer	3.08e-05	0.000541	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ENO2—muscle cancer	3.08e-05	0.000541	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ENO2—muscle cancer	3.08e-05	0.000541	CbGpPWpGaD
Bortezomib—Thrombocytopenia—Doxorubicin—muscle cancer	3.08e-05	0.000302	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—muscle cancer	3.07e-05	0.000301	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—muscle cancer	3.05e-05	0.000299	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—muscle cancer	3.04e-05	0.000298	CcSEcCtD
Bortezomib—PSMB8—Metabolism—ENO2—muscle cancer	3.04e-05	0.000534	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KIT—muscle cancer	3.01e-05	0.00053	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KIT—muscle cancer	3.01e-05	0.00053	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KIT—muscle cancer	3.01e-05	0.00053	CbGpPWpGaD
Bortezomib—PSMB5—Disease—FOXO4—muscle cancer	3e-05	0.000527	CbGpPWpGaD
Bortezomib—PSMB1—Disease—FOXO4—muscle cancer	3e-05	0.000527	CbGpPWpGaD
Bortezomib—PSMB2—Disease—FOXO4—muscle cancer	3e-05	0.000527	CbGpPWpGaD
Bortezomib—Anorexia—Doxorubicin—muscle cancer	3e-05	0.000294	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—muscle cancer	2.99e-05	0.000293	CcSEcCtD
Bortezomib—PSMB1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.99e-05	0.000525	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.99e-05	0.000525	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.99e-05	0.000525	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KIT—muscle cancer	2.97e-05	0.000522	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Methotrexate—muscle cancer	2.97e-05	0.000291	CcSEcCtD
Bortezomib—PSMB8—Disease—FOXO4—muscle cancer	2.95e-05	0.00052	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.94e-05	0.000518	CbGpPWpGaD
Bortezomib—Hypotension—Doxorubicin—muscle cancer	2.94e-05	0.000288	CcSEcCtD
Bortezomib—PSMA1—Disease—FOXO1—muscle cancer	2.92e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMD1—Disease—FOXO1—muscle cancer	2.91e-05	0.000511	CbGpPWpGaD
Bortezomib—PSMD2—Disease—FOXO1—muscle cancer	2.89e-05	0.000509	CbGpPWpGaD
Bortezomib—Urticaria—Methotrexate—muscle cancer	2.88e-05	0.000283	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—muscle cancer	2.87e-05	0.000281	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—muscle cancer	2.87e-05	0.000281	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.86e-05	0.000281	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—muscle cancer	2.84e-05	0.000279	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—muscle cancer	2.82e-05	0.000277	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—muscle cancer	2.8e-05	0.000275	CcSEcCtD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.79e-05	0.000491	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FOXO4—muscle cancer	2.77e-05	0.000487	CbGpPWpGaD
Bortezomib—Dyspepsia—Doxorubicin—muscle cancer	2.77e-05	0.000271	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—FOXO4—muscle cancer	2.76e-05	0.000485	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FOXO4—muscle cancer	2.74e-05	0.000482	CbGpPWpGaD
Bortezomib—Decreased appetite—Doxorubicin—muscle cancer	2.73e-05	0.000268	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CNR1—muscle cancer	2.72e-05	0.000478	CbGpPWpGaD
Bortezomib—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.71e-05	0.000266	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—muscle cancer	2.71e-05	0.000266	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—CNR1—muscle cancer	2.7e-05	0.000476	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CNR1—muscle cancer	2.69e-05	0.000473	CbGpPWpGaD
Bortezomib—Pain—Doxorubicin—muscle cancer	2.69e-05	0.000264	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—muscle cancer	2.69e-05	0.000264	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—muscle cancer	2.67e-05	0.000262	CcSEcCtD
Bortezomib—PSMB1—Cell Cycle—CDKN2A—muscle cancer	2.67e-05	0.000469	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—CDKN2A—muscle cancer	2.67e-05	0.000469	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—CDKN2A—muscle cancer	2.67e-05	0.000469	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—CDKN2A—muscle cancer	2.63e-05	0.000463	CbGpPWpGaD
Bortezomib—Asthenia—Methotrexate—muscle cancer	2.6e-05	0.000255	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—muscle cancer	2.59e-05	0.000254	CcSEcCtD
Bortezomib—PSMB1—Cell Cycle—MDM2—muscle cancer	2.59e-05	0.000455	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—MDM2—muscle cancer	2.59e-05	0.000455	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—MDM2—muscle cancer	2.59e-05	0.000455	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Doxorubicin—muscle cancer	2.57e-05	0.000252	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—muscle cancer	2.57e-05	0.000252	CcSEcCtD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.56e-05	0.00045	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—MDM2—muscle cancer	2.55e-05	0.000449	CbGpPWpGaD
Bortezomib—Urticaria—Doxorubicin—muscle cancer	2.5e-05	0.000245	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—muscle cancer	2.48e-05	0.000244	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—muscle cancer	2.48e-05	0.000244	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—muscle cancer	2.48e-05	0.000244	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—PTCH1—muscle cancer	2.44e-05	0.000429	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTCH1—muscle cancer	2.44e-05	0.000429	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTCH1—muscle cancer	2.44e-05	0.000429	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KIT—muscle cancer	2.41e-05	0.000424	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTCH1—muscle cancer	2.41e-05	0.000423	CbGpPWpGaD
Bortezomib—Dizziness—Methotrexate—muscle cancer	2.4e-05	0.000235	CcSEcCtD
Bortezomib—PSMD1—Immune System—KIT—muscle cancer	2.4e-05	0.000422	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—FOXO1—muscle cancer	2.4e-05	0.000422	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—FOXO1—muscle cancer	2.4e-05	0.000422	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—FOXO1—muscle cancer	2.4e-05	0.000422	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KIT—muscle cancer	2.39e-05	0.00042	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—MDM2—muscle cancer	2.37e-05	0.000417	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—MDM2—muscle cancer	2.37e-05	0.000417	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—MDM2—muscle cancer	2.37e-05	0.000417	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—FOXO1—muscle cancer	2.36e-05	0.000416	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—MDM2—muscle cancer	2.34e-05	0.000411	CbGpPWpGaD
Bortezomib—Hypersensitivity—Doxorubicin—muscle cancer	2.32e-05	0.000227	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—muscle cancer	2.31e-05	0.000226	CcSEcCtD
Bortezomib—Rash—Methotrexate—muscle cancer	2.29e-05	0.000224	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—muscle cancer	2.29e-05	0.000224	CcSEcCtD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.29e-05	0.000402	CbGpPWpGaD
Bortezomib—Headache—Methotrexate—muscle cancer	2.27e-05	0.000223	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—muscle cancer	2.25e-05	0.000221	CcSEcCtD
Bortezomib—PSMA1—Disease—KIT—muscle cancer	2.23e-05	0.000391	CbGpPWpGaD
Bortezomib—Pruritus—Doxorubicin—muscle cancer	2.22e-05	0.000218	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—IGF2—muscle cancer	2.22e-05	0.000391	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KIT—muscle cancer	2.21e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB1—Disease—FOXO1—muscle cancer	2.21e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB5—Disease—FOXO1—muscle cancer	2.21e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB2—Disease—FOXO1—muscle cancer	2.21e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IGF2—muscle cancer	2.21e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KIT—muscle cancer	2.2e-05	0.000388	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—FH—muscle cancer	2.2e-05	0.000387	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IGF2—muscle cancer	2.2e-05	0.000387	CbGpPWpGaD
Bortezomib—PSMB8—Disease—FOXO1—muscle cancer	2.18e-05	0.000384	CbGpPWpGaD
Bortezomib—Nausea—Methotrexate—muscle cancer	2.16e-05	0.000211	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—muscle cancer	2.15e-05	0.000211	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—FOXO4—muscle cancer	2.1e-05	0.000369	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FOXO4—muscle cancer	2.1e-05	0.000369	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FOXO4—muscle cancer	2.1e-05	0.000369	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.08e-05	0.000366	CbGpPWpGaD
Bortezomib—Dizziness—Doxorubicin—muscle cancer	2.08e-05	0.000204	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—FOXO4—muscle cancer	2.07e-05	0.000364	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CNR1—muscle cancer	2.06e-05	0.000362	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CNR1—muscle cancer	2.06e-05	0.000362	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CNR1—muscle cancer	2.06e-05	0.000362	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FOXO1—muscle cancer	2.04e-05	0.00036	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FOXO1—muscle cancer	2.04e-05	0.000358	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CNR1—muscle cancer	2.03e-05	0.000357	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FOXO1—muscle cancer	2.03e-05	0.000356	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—FH—muscle cancer	2.02e-05	0.000355	CbGpPWpGaD
Bortezomib—Vomiting—Doxorubicin—muscle cancer	2e-05	0.000196	CcSEcCtD
Bortezomib—Rash—Doxorubicin—muscle cancer	1.98e-05	0.000194	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—muscle cancer	1.98e-05	0.000194	CcSEcCtD
Bortezomib—Headache—Doxorubicin—muscle cancer	1.97e-05	0.000193	CcSEcCtD
Bortezomib—PSMA1—Cell Cycle—TP53—muscle cancer	1.96e-05	0.000345	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—muscle cancer	1.95e-05	0.000343	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—muscle cancer	1.94e-05	0.000341	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—MDM2—muscle cancer	1.9e-05	0.000334	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—MDM2—muscle cancer	1.89e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—MDM2—muscle cancer	1.88e-05	0.000331	CbGpPWpGaD
Bortezomib—Nausea—Doxorubicin—muscle cancer	1.87e-05	0.000183	CcSEcCtD
Bortezomib—PSMB1—Immune System—KIT—muscle cancer	1.83e-05	0.000321	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KIT—muscle cancer	1.83e-05	0.000321	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KIT—muscle cancer	1.83e-05	0.000321	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—FH—muscle cancer	1.8e-05	0.000317	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KIT—muscle cancer	1.8e-05	0.000317	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.78e-05	0.000313	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MED12—muscle cancer	1.77e-05	0.00031	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MDM2—muscle cancer	1.75e-05	0.000308	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MDM2—muscle cancer	1.74e-05	0.000307	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MDM2—muscle cancer	1.74e-05	0.000305	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—muscle cancer	1.69e-05	0.000297	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KIT—muscle cancer	1.69e-05	0.000297	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KIT—muscle cancer	1.69e-05	0.000297	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KIT—muscle cancer	1.69e-05	0.000297	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF2—muscle cancer	1.68e-05	0.000296	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF2—muscle cancer	1.68e-05	0.000296	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF2—muscle cancer	1.68e-05	0.000296	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—muscle cancer	1.68e-05	0.000296	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—muscle cancer	1.67e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KIT—muscle cancer	1.66e-05	0.000292	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF2—muscle cancer	1.66e-05	0.000292	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—FH—muscle cancer	1.66e-05	0.000291	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—FH—muscle cancer	1.64e-05	0.000289	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ENO2—muscle cancer	1.61e-05	0.000283	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KIT—muscle cancer	1.56e-05	0.000274	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KIT—muscle cancer	1.55e-05	0.000273	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FOXO1—muscle cancer	1.55e-05	0.000273	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FOXO1—muscle cancer	1.55e-05	0.000273	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FOXO1—muscle cancer	1.55e-05	0.000273	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KIT—muscle cancer	1.54e-05	0.000271	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FOXO1—muscle cancer	1.53e-05	0.000269	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—muscle cancer	1.49e-05	0.000261	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—muscle cancer	1.49e-05	0.000261	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—muscle cancer	1.49e-05	0.000261	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—muscle cancer	1.46e-05	0.000258	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MDM2—muscle cancer	1.44e-05	0.000253	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MDM2—muscle cancer	1.44e-05	0.000253	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MDM2—muscle cancer	1.44e-05	0.000253	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MDM2—muscle cancer	1.42e-05	0.000249	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—muscle cancer	1.41e-05	0.000249	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—muscle cancer	1.41e-05	0.000248	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—FH—muscle cancer	1.4e-05	0.000247	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—muscle cancer	1.4e-05	0.000246	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MDM2—muscle cancer	1.33e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MDM2—muscle cancer	1.33e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MDM2—muscle cancer	1.33e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MDM2—muscle cancer	1.31e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—muscle cancer	1.28e-05	0.000225	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—muscle cancer	1.28e-05	0.000225	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—muscle cancer	1.28e-05	0.000225	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—muscle cancer	1.26e-05	0.000222	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.26e-05	0.000221	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MED12—muscle cancer	1.24e-05	0.000219	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MDM2—muscle cancer	1.23e-05	0.000216	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MDM2—muscle cancer	1.22e-05	0.000215	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MDM2—muscle cancer	1.22e-05	0.000214	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KIT—muscle cancer	1.18e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KIT—muscle cancer	1.18e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KIT—muscle cancer	1.18e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KIT—muscle cancer	1.16e-05	0.000205	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MED12—muscle cancer	1.14e-05	0.000201	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO2—muscle cancer	1.13e-05	0.000199	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FH—muscle cancer	1.08e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—muscle cancer	1.07e-05	0.000189	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—muscle cancer	1.07e-05	0.000189	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—muscle cancer	1.07e-05	0.000189	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—muscle cancer	1.06e-05	0.000186	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO2—muscle cancer	1.04e-05	0.000183	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MED12—muscle cancer	1.02e-05	0.000179	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MED12—muscle cancer	9.36e-06	0.000165	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—muscle cancer	9.32e-06	0.000164	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MDM2—muscle cancer	9.3e-06	0.000164	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MDM2—muscle cancer	9.3e-06	0.000164	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MDM2—muscle cancer	9.3e-06	0.000164	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MED12—muscle cancer	9.28e-06	0.000163	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—muscle cancer	9.28e-06	0.000163	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—muscle cancer	9.27e-06	0.000163	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—muscle cancer	9.23e-06	0.000162	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MDM2—muscle cancer	9.17e-06	0.000161	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.87e-06	0.000156	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—muscle cancer	8.53e-06	0.00015	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—muscle cancer	8.46e-06	0.000149	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.13e-06	0.000143	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MED12—muscle cancer	7.93e-06	0.000139	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.26e-06	0.000128	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—muscle cancer	7.23e-06	0.000127	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—muscle cancer	7.06e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—muscle cancer	7.06e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—muscle cancer	7.06e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—muscle cancer	7.04e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—muscle cancer	7.01e-06	0.000123	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—muscle cancer	6.97e-06	0.000123	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—muscle cancer	6.96e-06	0.000122	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.62e-06	0.000116	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MED12—muscle cancer	6.12e-06	0.000108	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.65e-06	9.94e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—muscle cancer	5.61e-06	9.86e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—muscle cancer	5.58e-06	9.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—muscle cancer	5.34e-06	9.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—muscle cancer	5.34e-06	9.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—muscle cancer	5.34e-06	9.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—muscle cancer	5.26e-06	9.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—muscle cancer	3.95e-06	6.95e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—muscle cancer	3.62e-06	6.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—muscle cancer	3.23e-06	5.68e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—muscle cancer	2.97e-06	5.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—muscle cancer	2.95e-06	5.18e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—muscle cancer	2.52e-06	4.43e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.94e-06	3.42e-05	CbGpPWpGaD
